secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2026-07-06T20:15:17+00:00
Accession:  0001193125-26-296201
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight and Alcon enter collaboration to develop adjustable PCIOLs; $60M upfront, up to $140M milestones
--------------------------------------------------------------------------------

- RxSight receives $60M upfront; potential $70M feasibility milestone, $30M FDA submission milestone, $40M approval milestone.
- Alcon to pay 30% royalties on net sales of collaboration products; RxSight to develop and manufacture, Alcon to commercialize globally.
- Collaboration combines RxSight's light-adjustable technology with Alcon's presbyopia-correcting IOL optics for post-operative fine-tuning.
- Agreement includes non-exclusive licenses; RxSight retains U.S. regulatory approvals and will supply LDD devices.
- Deal could accelerate adoption of adjustable IOLs; Alcon is global eye care leader (SIX/NYSE: ALC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526296201/0001193125-26-296201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526296201/rxst-20260630.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-296201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer